4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one (Compound)

Description: A compound in the knowledge graph

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View 4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one's neighborhood in the knowledge graph.

Submit

Knowledge Graph Assertions

Source	Relation	Target	Evidence
5-(7-(benzyloxy)quinazolin-4-ylamino)-4-fluoro-2-methylphenol Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	0.22845359146595
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	Negatively regulates Knowledge Graph Relation (Entity type)	PNO1 Gene (Entity type)	-0.0087315105
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	PIK-90 Compound (Entity type)	0.5961629152297974
PP-110 Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	0.7370878458023071
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	Negatively regulates Knowledge Graph Relation (Entity type)	DDX21 Gene (Entity type)	-0.0078072967
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	PI-828 Compound (Entity type)	0.5788675546646118
1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Compound (Entity type)	In similarity relationship with Knowledge Graph Relation (Entity type)	4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	0.399019181728363
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	Negatively regulates Knowledge Graph Relation (Entity type)	LTF Gene (Entity type)	-0.009111033
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	Negatively regulates Knowledge Graph Relation (Entity type)	IER3 Gene (Entity type)	-0.008051567
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one Compound (Entity type)	Positively regulates Knowledge Graph Relation (Entity type)	CDC25B Gene (Entity type)	0.009626604

5-(7-(benzyloxy)quinazolin-4-ylamino)-4-fluoro-2-methylphenol
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
0.22845359146595

4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
Negatively regulates
Knowledge Graph Relation (Entity type)
PNO1
Gene (Entity type)
-0.0087315105

4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
PIK-90
Compound (Entity type)
0.5961629152297974

PP-110
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
0.7370878458023071

4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
Negatively regulates
Knowledge Graph Relation (Entity type)
DDX21
Gene (Entity type)
-0.0078072967

4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
PI-828
Compound (Entity type)
0.5788675546646118

1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea
Compound (Entity type)
In similarity relationship with
Knowledge Graph Relation (Entity type)
4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
0.399019181728363

4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
Negatively regulates
Knowledge Graph Relation (Entity type)
LTF
Gene (Entity type)
-0.009111033

4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
Negatively regulates
Knowledge Graph Relation (Entity type)
IER3
Gene (Entity type)
-0.008051567

4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
Compound (Entity type)
Positively regulates
Knowledge Graph Relation (Entity type)
CDC25B
Gene (Entity type)
0.009626604

DISPLAY PER PAGE

Knowledge Graph Assertions

	Source	Relation	Target	Evidence
Loading results...

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.